Patents by Inventor Andrew Thomas Maynard

Andrew Thomas Maynard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRPML modulators
    Patent number: 12698266
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: August 4, 2026
    Assignee: Casma Therapeutics, Inc.
    Inventors: Jorge Garcia Fortanet, Jeffrey Owen Saunders, Harit Umesh Vora, Jian Lin, Andrew Thomas Maynard, Erik Lee Meredith
  • TRPML MODULATORS
    Publication number: 20230416262
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 6, 2021
    Publication date: December 28, 2023
    Inventors: Andrew Thomas Maynard, Erik Lee Meredith, Jeffrey Owen Saunders, Jian Lin, Jorge Garcia Fortanet
  • TRPML MODULATORS
    Publication number: 20230104936
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 6, 2023
    Inventors: Jorge Garcia Fortanet, Jeffrey Owen Saunders, Harit Umesh Vora, Jian Lin, Andrew Thomas Maynard, Erik Lee Meredith
  • Inhibitors of ion channels
    Patent number: 8741934
    Abstract: The invention is directed to compounds of Formula I in which: R5, R6, B and Z are defined supra.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: June 3, 2014
    Assignees: Pfizer Limited, Icagen, Inc.
    Inventors: Brian Edward Marron, Paul Christopher Fritch, Christopher John Markworth, Andrew Thomas Maynard, Nigel Alan Swain
  • Inhibitors of Ion Channels
    Publication number: 20130072471
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
    Type: Application
    Filed: November 15, 2012
    Publication date: March 21, 2013
    Inventors: Brian Edward Marron, Paul Christopher Fritch, Christopher John Markworth, Andrew Thomas Maynard, Nigel Alan Swain
  • Heterocyclic sulfonamides as inhibitors of ion channels
    Patent number: 8357711
    Abstract: The invention is directed to compounds of the formula in which R5, R6 B and Z are defined supra.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: January 22, 2013
    Assignees: Pfizer Limited, Icagen, Inc.
    Inventors: Brian Edward Marron, Paul Christopher Fritch, Christopher John Markworth, Andrew Thomas Maynard, Nigel Alan Swain
  • INHIBITORS OF ION CHANNELS
    Publication number: 20090143358
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
    Type: Application
    Filed: March 20, 2008
    Publication date: June 4, 2009
    Applicants: ICAgen, Inc., Pfizer Limited
    Inventors: Brian Edward Marron, Paul Christopher Fritch, Christopher John Markworth, Andrew Thomas Maynard, Nigel Alan Swain